Fluidigm takes another shot at $86M IPO

Genetics instruments maker Fluidigm Corporation is once again filing for an IPO. Its first attempt came in 2008 but was scuttled when the public markets took a turn for the worse. The company plans to raise $86 million--about the same amount as it aimed for in 2008--but says the shares to be offered and the price range for the offering have not yet been determined. Deutsche Bank Securities and Piper Jaffray & Co. are acting as book-runners for the offering.

Fluidigm develops, manufactures and markets microfluidics products designed to make laboratory testing more efficient and precise. According to its SEC filing, the South San Francisco-based company markets three microfluidic systems including eight different commercial chips to leading pharmaceutical and biotechnology companies, academic institutions, diagnostic laboratories and Ag-Bio companies. It has sold its systems to over 200 customers in over 20 countries worldwide. Fluidigm says it will use the financing to increase market penetration of its microfluidic systems and continue to develop new technology. The developer will trade under the symbol "FLDM."

- check out Fluidigm's release
- here's the SEC filing for more

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.